| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10385341 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(10 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10968453 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(10 years from now) | |
| US10669546 | BIOGEN MA | Compositions for modulating SOD-1 expression |
Apr, 2035
(10 years from now) | |
Qalsody is owned by Biogen Ma.
Qalsody contains Tofersen.
Qalsody has a total of 3 drug patents out of which 0 drug patents have expired.
Qalsody was authorised for market use on 25 April, 2023.
Qalsody is available in solution;intrathecal dosage forms.
Qalsody can be used as treatment of amyotrophic lateral sclerosis (als) in adults who have a mutation in the superoxide dismutase 1 (sod1) gene.
Drug patent challenges can be filed against Qalsody from 26 April, 2027.
The generics of Qalsody are possible to be released after 01 April, 2035.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-432) | Apr 25, 2030 |
| New Chemical Entity Exclusivity(NCE) | Apr 25, 2028 |
Drugs and Companies using TOFERSEN ingredient
NCE-1 date: 26 April, 2027
Market Authorisation Date: 25 April, 2023
Treatment: Treatment of amyotrophic lateral sclerosis (als) in adults who have a mutation in the superoxide dismutase 1 (sod1) gene
Dosage: SOLUTION;INTRATHECAL
QALSODY family patents
